Chemotherapeutics

Mechanisms

Chemotherapy agents act through diverse cytotoxic mechanisms - alkylating agents (direct DNA damage), antimetabolites (interfering with nucleotide synthesis), and antimitotics (disrupting mitotic spindle formation) among the classic mechanistic categories - each class exploiting cancer cells' relatively higher proliferation rate, but with characteristic organ toxicity reflecting collateral damage to other rapidly dividing normal tissues (marrow, gut epithelium, hair follicles)
Cytotoxic mechanism targets rapidly dividing cells relatively non-selectively - this explains the shared toxicity pattern across chemotherapy classes (bone marrow suppression, mucositis, alopecia, gastrointestinal toxicity) reflecting collateral damage to normal rapidly dividing tissues, distinct from the more organ-specific mechanisms of individual agents (e.g. specific cardiotoxicity with anthracyclines, specific neurotoxicity with vinca alkaloids/platinum agents)

Central to systemic cancer treatment across the majority of malignancies, though increasingly used alongside or superseded by targeted and immunotherapy agents for specific cancer types

Baseline organ function assessment (cardiac function before anthracyclines, renal function before platinum agents, pulmonary function before bleomycin) anticipates specific known organ toxicity risks before treatment begins
Regular blood count monitoring throughout treatment given universal marrow suppression risk across essentially all cytotoxic chemotherapy classes

See for the detailed organ-specific toxicity management approach
Growth factor support (e.g. G-CSF) and antiemetic prophylaxis are used proactively in specific high-risk regimens rather than only reactively once toxicity develops

Bone marrow suppression and febrile neutropenia risk (shared across the class), anthracycline cardiotoxicity, platinum agent nephrotoxicity/neurotoxicity, cumulative dose-limiting toxicity tracking (particularly relevant to anthracyclines given lifetime cumulative dose limits)
Chemotherapy's shared toxicity pattern (marrow suppression, mucositis, alopecia, GI toxicity) reflects collateral damage to normal rapidly-dividing tissues rather than a drug-class-specific mechanism - this is why nearly every cytotoxic chemotherapy agent, regardless of its specific molecular target, produces this broadly similar toxicity profile even though their cancer-killing mechanisms differ substantially

4 more sections, plus exam facts

Premium unlocks every note across every specialty, and the full exam fact library behind it.